Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
|Videos|May 16, 2022
Dr. Fleming on imaging agent 18F-rhPSMA-7.3 and SPOTLIGHT trial in prostate cancer
Author(s)Urology Times staff
Advertisement
Mark Fleming, MD, Virginia Oncology Associates (US Oncology Network), discusses the novel PET imaging agent 18F-rhPSMA-7.3 and findings with the agent in the
Advertisement
Related to this article
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.
Early neurophysiology and pressure-flow research directly underpin modern urodynamics, whereas Turner-Warwick's restorative philosophy, according to Sasha Vereecken, BScN, RN.
This FAQ outlines key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
5